


Major R&D Pipeline

Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

January 2010
DAIICHI SANKYO CO., LTD.

Therapeutic Area	Main Existing Product	Phase1	Phase2	Phase3	Application
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor/Sevikar Welchol Effient/Efient Olmetec Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrhythm Bepricor	DB-772d(US/EU) (oral factor Xa inhibitor)	★CS-866CMB(JP) (Olmesartan, Hydrochlorothiazide combination) DU-176b(US/EU) (Edoxaban / VTE / oral factor Xa inhibitor) CS-747(JP) (Prasugrel / anti-platelet agent)	★CS-747(US/EU) (Prasugrel / ACS-MM / anti-platelet agent) DU-176b(US/EU/JP/Asia) (Edoxaban / atrial fibrillation / oral factor Xa inhibitor) DU-176b(JP) (Edoxaban / VTE / oral factor Xa inhibitor) 	★CS-866AZ(JP) (Olmesartan, Azelnidipine combination) ★CS-8635(US) (Olmesartan, Amlodipine, Hydrochlorothiazide combination) ★CS-8635(EU) (Olmesartan, Amlodipine, Hydrochlorothiazide combination)
Glucose metabolic disorders	Welchol Fastic	CS-1036(JP/Asia) (glucose absorption inhibitor)			
Infectious diseases	Levaquin / Tavanic Banan Cravit	CS-8958(US/EU) (Laninamivir / anti-influenza / co-development with Biota)		CS-8958(JP) (Laninamivir / anti-influenza)	★Levofloxacin inj(JP) (new quinolone)
Cancer	Topotecin Krestin	U3-1287(US) (anti-HER3 antibody) CS-1008(JP) (Tigatuzumab/anti-DR5 antibody)	CS-1008(US/EU) (Tigatuzumab / anti-DR5 antibody) CS-7017(US) (PPARγ activator) DE-766(JP) (Nimotuzumab / anti-EGFR antibody) ARQ 197(US/EU) (c-Met inhibitor)		
Immunological allergic diseases	Zyrtec	CS-0777(US/EU) (immunomodulator)	SUN13834(US) (chymase inhibitor)		
Bone/Joint diseases	Loxonin Mobic			AMG 162(JP) (Denosumab/bone metastases of cancer, osteoporosis / anti-RANKL antibody)	★CS-600G(JP) (Loxoprofen / gel)
Others	Venofor Evoxac Omnipaque Omniscan Visipaque Sonazoid Feron Urief		SUN11031(US/EU) (Human ghrelin / cachexia) ★DD-723-B(JP) (Perflubutane / ultrasonic contrast agent)	SUN11031(JP) (Human ghrelin/anorexia nervosa) SUN Y7017(JP) (Memantine / mild to moderate and severe dementia of Alzheimer type)	KMD-3213(China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia)

★Additional indications, new formulations etc.

Change from the announcement in October 2009

New(underline)

Change of Stage etc. CS-866AZ(JP / Approved), CS-8635(EU / Application)